TY - JOUR T1 - Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients JF - medRxiv DO - 10.1101/2020.03.13.20035428 SP - 2020.03.13.20035428 AU - Yunbao Pan AU - Xinran Li AU - Gui Yang AU - Junli Fan AU - Yueting Tang AU - Jin Zhao AU - Xinghua Long AU - Shuang Guo AU - Ziwu Zhao AU - Yinjuan Liu AU - Hanning Hu AU - Han Xue AU - Yirong Li Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/03/17/2020.03.13.20035428.abstract N2 - An outbreak of new coronavirus SARS-CoV-2 was occurred in Wuhan, China and rapidly spread to other cities and nations. The standard diagnostic approach that widely adopted in the clinic is nuclear acid detection by real-time RT-PCR. However, the false-negative rate of the technique is unneglectable and serological methods are urgently warranted. Here, we presented the colloidal gold-based immunochromatographic (ICG) strip targeting viral IgM or IgG antibody and compared it with real-time RT-PCR. The sensitivity of ICG assay with IgM and IgG combinatorial detection in nuclear acid confirmed cases were 11.1%, 92.9% and 96.8% at the early stage (1-7 days after onset), intermediate stage (8-14 days after onset), and late stage (more than 15 days), respectively. The ICG detection capacity in nuclear acid-negative suspected cases was 43.6%. In addition, the consistencies of whole blood samples with plasma were 100% and 97.1% in IgM and IgG strips, respectively. In conclusion, serological ICG strip assay in detecting SARS-CoV-2 infection is both sensitive and consistent, which is considered as an excellent supplementary approach in clinical application.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Key Research and Development Program of China (2018YFE0204500)Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request. ER -